Related Experiment Video

Updated: Jun 23, 2025

Looking for Driver Pathways of Acquired Resistance to Targeted Therapy: Drug Resistant Subclone Generation and Sensitivity Restoring by Gene Knock-down
08:59

Looking for Driver Pathways of Acquired Resistance to Targeted Therapy: Drug Resistant Subclone Generation and Sensitivity Restoring by Gene Knock-down

Published on: December 11, 2017

7.2K

HER-2 positive gastric cancer: Current targeted treatments

Rama Rao Malla1, Haasita Reddy Nellipudi2, Mundla Srilatha3

  • 1Cancer Biology Laboratory, Department of Biochemistry and Bioinformatics, Institute of Science, Gandhi Institute of Technology and Management (Deemed to be University), Visakhapatnam, AP 530045, India.

International Journal of Biological Macromolecules
|June 21, 2024
PubMed

Insights

Human Epidermal growth factor Receptor 2 (HER2) amplification drives gastric cancer (GC) metastasis and drug resistance. Targeting HER2 with novel therapies, including phytochemicals and nanoparticles, shows promise for improved patient outcomes.

Area of Science:

  • Oncology
  • Molecular Biology
  • Cancer Research

Background:

  • Gastric cancer (GC) is a highly metastatic disease often characterized by Human Epidermal growth factor Receptor 2 (HER2) amplification.
  • Aberrant HER2 expression is linked to increased metastasis, therapeutic resistance, and tumor recurrence in GC.
  • HER2 amplification promotes drug resistance through mechanisms like upregulating DNA repair enzymes and drug efflux proteins.

Purpose of the Study:

  • To review recent advancements in HER2-mediated mechanisms and signaling pathways in GC.
  • To explore the role of HER2 as a targetable driver in gastric cancer.
  • To discuss preclinical investigations of adjunct therapies for HER2-positive GC.

Main Methods:

  • Literature review of recent advances in HER2-mediated mechanisms in GC.
  • Analysis of upstream and downstream signaling pathways influenced by HER2.
  • Examination of preclinical research on trastuzumab-sensitizing agents.

Main Results:

  • HER2 amplification contributes to GC progression and resistance to therapies.
  • HER2 influences cancer stem cell properties and oncogenic signaling.
  • Preclinical studies indicate potential of phytochemicals, chemotherapeutics, and nanoparticles as adjunct therapies.

Conclusions:

  • HER2 is a critical targetable driver in HER2-positive GC.
  • Adjunct therapies targeting HER2 show promise for improving treatment efficacy.
  • Further research and clinical trials are warranted to enhance management of HER2-positive GC.
Keywords:
Adjunct therapiesGastric cancerMetastasisResistanceSignaling

More Related Videos

Gene Regulation and Targeted Therapy in Gastric Cancer Peritoneal Metastasis: Radiological Findings from Dual Energy CT and PET/CT10:28

Gene Regulation and Targeted Therapy in Gastric Cancer Peritoneal Metastasis: Radiological Findings from Dual Energy CT and PET/CT

Published on: January 22, 2018

11.1K
Author Spotlight: Genetic Profiling for Fluorouracil Response in Gastric Cancer06:21

Author Spotlight: Genetic Profiling for Fluorouracil Response in Gastric Cancer

Published on: May 10, 2024

670

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.5K
Peptic Ulcer Disease IV: Management01:26

Peptic Ulcer Disease IV: Management

Medical treatment strategies for peptic ulcers encompass various methods. The primary goal of treatment is to diminish gastric acidity and strengthen mucosal defense mechanisms.
The therapeutic approach involves ensuring adequate rest, implementing drug therapy, promoting smoking cessation, making dietary modifications, and emphasizing long-term follow-up care.
Pharmacological management
The prevailing therapy for peptic ulcers involves a combination of managing the patient's current...
87
Treating Helicobacter pylori in Peptic Ulcers: Antimicrobial Therapy01:16

Treating Helicobacter pylori in Peptic Ulcers: Antimicrobial Therapy

Helicobacter pylori, a resilient gram-negative bacterium, can thrive in the stomach's harsh, acidic environment. Infection with H. pylori leads to a cascade of events within the stomach lining. One of the critical disruptions caused by this bacterium is the interference with somatostatin production, a hormone responsible for regulating acid secretion. This interference tips the balance, escalating acid secretion and diminishing bicarbonate levels. This imbalance compromises the defensive...
358
Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists01:28

Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists

Neurokinin 1 (NK1) receptors are distributed across the GI tract, vagal afferents, and key CNS regions including the central vomiting center and chemoreceptor trigger zone (CTZ) Chemotherapy agents stimulate enterochromaffin cells in the gastrointestinal (GI) tract to release large amounts of substance P (SP). SP is a neuropeptide released by specific sensory nerves in response to many different stressors, including those in the GI mucosa affected by chemotherapy.  SP binds and activates...
159
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
6.5K
Cancer Vaccines01:30

Cancer Vaccines

Cancer treatment vaccines are a rapidly evolving field that offers a promising approach to immunotherapy. Unlike traditional vaccines that prevent diseases, cancer treatment vaccines are designed to treat existing cancers by stimulating the immune system to recognize and attack cancer cells.
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
352